The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Maria Soares; Jorge Correia; José Cabeçadas; Conceição Peleteiro; Fernando Ferreira

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Maria Soares
, Jorge Correia
, José Cabeçadas
, Conceição Peleteiro
, Fernando Ferreira

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

Original language	English
Title of host publication	Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012
Pages	9-17
Number of pages	9
Publication status	Published - 2012
Externally published	Yes
Event	1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 - Vilamoura, Algarve, Portugal Duration: 1 Feb 2012 → 4 Feb 2012

Publication series

Name	Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

Conference

Conference	1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012
Country/Territory	Portugal
City	Vilamoura, Algarve
Period	1/02/12 → 4/02/12

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Soares, M., Correia, J., Cabeçadas, J., Peleteiro, C., & Ferreira, F. (2012). The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. In Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 (pp. 9-17). (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

Soares, Maria ; Correia, Jorge ; Cabeçadas, José et al. / The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. pp. 9-17 (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

@inproceedings{014739bfa5f846848502a734455387a1,

title = "The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma",

abstract = "The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3\%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.",

author = "Maria Soares and Jorge Correia and Jos{\'e} Cabe{\c c}adas and Concei{\c c}{\~a}o Peleteiro and Fernando Ferreira",

year = "2012",

language = "English",

isbn = "9789898425942",

series = "Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012",

pages = "9--17",

booktitle = "Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012",

note = "1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 ; Conference date: 01-02-2012 Through 04-02-2012",

}

Soares, M, Correia, J, Cabeçadas, J, Peleteiro, C & Ferreira, F 2012, The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. in Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012, pp. 9-17, 1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012, Vilamoura, Algarve, Portugal, 1/02/12.

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. / Soares, Maria; Correia, Jorge; Cabeçadas, José et al.
Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. p. 9-17 (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

AU - Soares, Maria

AU - Correia, Jorge

AU - Cabeçadas, José

AU - Peleteiro, Conceição

AU - Ferreira, Fernando

PY - 2012

Y1 - 2012

N2 - The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

AB - The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

UR - https://www.scopus.com/pages/publications/84861972925

M3 - Conference contribution

AN - SCOPUS:84861972925

SN - 9789898425942

T3 - Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

SP - 9

EP - 17

BT - Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

T2 - 1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

Y2 - 1 February 2012 through 4 February 2012

ER -

Soares M, Correia J, Cabeçadas J, Peleteiro C, Ferreira F. The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. In Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. p. 9-17. (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Abstract

Publication series

Conference

UN SDGs

Other files and links

Fingerprint

Cite this